We've recently highlighted how right-to-work states, which the Biden Administration and Congressional…
CFIF on Twitter CFIF on YouTube
Amazon Workers Soundly Reject Unionization, and NR's Kevin Williamson Highlights Another Great Reason Why: Big-Labor Corruption

We've recently highlighted how right-to-work states, which the Biden Administration and Congressional leftists hope to abolish, dramatically outperform forced-union states in terms of job growth, manufacturing and household consumption.  Worker freedom from Big Labor bosses is a leading reason why in a high-profile vote, Amazon workers in Alabama voted to reject unionization by a 71% to 29% margin last week.

In a phenomenal new piece, National Review's Kevin Williamson offers another reason for rejecting unionization that we mustn't ignore:  big labor bosses' widespread corruption.  Williamson lists a litany of union officials convicted and sentenced for embezzlement and other misuse of members' hard-earned dues - in 2020 alone.  Accordingly, the leftist anti-capitalist drumbeat…[more]

April 12, 2021 • 01:05 PM

Liberty Update

CFIFs latest news, commentary and alerts delivered to your inbox.
Jester's CourtroomLegal tales stranger than stranger than fiction: Ridiculous and sometimes funny lawsuits plaguing our courts.
Home Press Room CFIF Opposes State Attorneys General “March-In” Demand on Remdesivir
CFIF Opposes State Attorneys General “March-In” Demand on Remdesivir Print
Thursday, August 06 2020

ALEXANDRIA, VA – This week, a group of state attorneys general issued a joint letter to the United States Department of Health and Human Services (HHS), National Institutes of Health (NIH) and Food and Drug Administration (FDA) demanding that the federal government employ so-called “march-in” rights under the Bayh-Dole Act of 1980 to disregard Gilead Sciences, Inc.’s patent rights on its antiviral drug Remdesivir, or allow their states to do so.  The Center for Individual Freedom (CFIF) strongly opposes their demand.  

“If you seek to bring pharmaceutical innovation to a grinding halt, and deprive Americans of lifesaving drugs, the best way to do it is to flagrantly disregard patent protections for pharmaceutical innovators,” said Timothy Lee, CFIF’s Senior Vice President of Legal and Public Affairs.  “Unfortunately, that’s precisely the path that a misguided group of state attorneys general have decided to pursue.  Violating innovators’ patent rights won’t make drugs cheaper, it will only deprive consumers of potentially beneficial drugs entirely.  America currently produces two-thirds of all new drugs worldwide, and that’s because our nation honors and protects patent rights, it doesn’t violate them,” Lee added.    

“It’s particularly galling that the attorneys’ general seek to leverage the Bayh-Dole Act of 1980 to facilitate their scheme, and as we celebrate the law’s 40th anniversary to boot,” Lee continued.  “The Bayh-Dole Act was passed in order to extend patent rights to universities and nonprofit research entities whose research was assisted by federal funds, not weaken them.”  

Prior to Bayh-Dole, very few innovations partially funded by federal dollars were ever commercially pursued – only 390 in the year prior to its passage.  Forty years later, however, that number approaches 7,500, with over 420,000 inventions and 13,000 new startup enterprises formed.  

In the case of Remdesivir, Gilead Sciences has invested billions of dollars in research, development, testing and now manufacturing of the antiviral drug, including over $1 billion this year alone to expand manufacturing capacity both domestically and abroad.  Moreover, Remdesivir’s patents are held by Gilead Sciences, not other researchers or entities that received federal funding at various points in the drug’s creation and production.  Accordingly, Bayh-Dole doesn’t offer the legal means by which the attorneys general seek to achieve their counterproductive ends.  

Fortunately, HHS officials have expressed strict opposition to this scheme.  “CFIF strongly encourages the Trump Administration, HHS, NIH and FDA to maintain their rejection, and instead strengthen rather than limit patent rights for America’s world-leading pharmaceutical innovators, particularly in this time of critical societal need,” Lee concluded.  

CFIF is a constitutional and free market advocacy organization with over 300,000 supporters and activists nationwide.  

###

Related Articles :
Quiz Question   
In which century were the first mandatory vaccination laws enacted in the United States?
More Questions
Notable Quote   
 
"A Monday New York Times front page headline on the explosion at a key Iranian nuclear facility claimed the 'Attack May Hurt Efforts to Reboot 2015 Deal.' On Tuesday, also on the front page, the paper declared that 'Israel's Role in Iran Blast Casts A Shadow on U.S. Nuclear Talks'.Get it? Making a new deal with Iran is a very good thing, anything that hurts the chance is a very bad thing, including…[more]
 
 
—Michael Goodwin, New York Post
— Michael Goodwin, New York Post
 
Liberty Poll   

Is it a reasonable use of taxpayer money for the federal government to provide a new $100 billion in tax credits to purchasers of electric vehicles?